ISPOR Europe 2022 Home
  • Program
    • Program
      • Session
      • Paper
    • Learning Formats
    • Plenary Sessions
    • Spotlight Sessions
    • Posters
    • Educational Symposia & HEOR Theater
    • Program Committee
    • Speaker & Poster Presenter Resources
    • Student Program
large-circle

ISPOR Europe 2022

6 - 9 November

  • Home
  • Events
  • Past Conferences
  • Program
  • Program
  • Session

  • Cemiplimab and Pembrolizumab for Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%: Number Needed to Treat and Cost of Preventing an Event in the Brazilian Private Healthcare System Perspective

    Nov 9, 2022, 09:00 AM
  • «
  • 261
  • 262
  • 263
  • 264 (current)
  • 265
  • 266
  • 267
  • 268
  • 269
  • 270
  • »
Quick Links
  • About
  • Media Center
  • Exhibits & Sponsorships
  • Contact Us
Policies & Legal
  • Antitrust Compliance
  • Code of Ethics
  • Cookie Policy
  • Diversity Policy
  • Funding Statement
  • Legal Disclaimer
  • Privacy Policy
  • Terms and Conditions

Subscribe

Join ISPOR

ISPOR–The Professional Society for
Health Economics and Outcomes Research

Copyright © 2018 ISPOR. All rights reserved.

International Society for Pharmacoeconomics and Outcomes Research, Inc

Website Design & Development by Matrix Group